Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of SPN-812 in Pediatric ADHD
NCT02736656Phase 3Active, not recruiting
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Feb 2016
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of viloxazine in attention deficit hyperactivity disorder (ADHD), sponsored by Supernus Pharmaceuticals, Inc.. Started Feb 2016; status: active, not recruiting.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02736656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736656.